Large-cap biotech stocks have been on a tear over the past few years, crushing the overall market return. Thanks to strong execution and a slew of new drug launches, these companies have found themselves flush with extra cash and have announced multibillion-dollar buyback programs. But are these share repurchase programs big enough to move the needle?
Hey, check out all the research scientist jobs. Post your resume today!
